LSU Health New Orleans Reveals Innovative Non-Addictive, Non-Toxic Pain Relief Formula

Tuesday, May 21, 2024

LSU Health New Orleans has unveiled a significant advancement in pain management with the introduction of a new non-opioid treatment option for acute, chronic, and neuropathic pain, as well as migraine headaches.

Boyd Professor and Director of the Neuroscience Center of Excellence, the research team has introduced a therapeutic candidate that promises relief without the organ toxicity or addiction risks associated with current pain medications.

Their findings, published in Nature's Scientific Reports, provide detailed insights into the compound's mechanism of action, affirming its potential in pain management.

"Research brings hope to millions grappling with pain while offering a solution to combat addiction. It also underscores the transformative possibilities of research conducted at the LSU Health Neuroscience Center of Excellence.

By leveraging the brain's natural mechanisms, we are tackling the opioid crisis head-on, developing safer and more effective pain management options for global use."

Exclusive licensing of the patents for this family of non-opioid pain therapeutics has been granted to South Rampart Pharma by LSU Health New Orleans. Supported by institutional, federal, and venture funding, the lead compound, SRP-001, has successfully passed Phase 1 human clinical trials, demonstrating both safety and efficacy.

Recently, the FDA has granted Fast Track designation for SRP-001 in acute pain treatment, recognizing its potential to address an urgent medical need and facilitating its progression to more comprehensive clinical trials.

CEO and co-founder of South Rampart Pharma, emphasizes the importance of innovative pain solutions, citing the prevalence of pain conditions worldwide. With existing treatments carrying risks of addiction and toxicity, the advancement of SRP-001 into Phase 2 randomized and controlled studies for acute and neuropathic pain is eagerly anticipated in the latter half of 2024.

Chancellor of LSU Health New Orleans, applauds Dr. Nicolas Bazan's groundbreaking discovery, highlighting the institution's commitment to advancing biomedical research, translating medical breakthroughs into clinical practice, and serving patients locally and globally.

The innovation holds promise in alleviating the burdens of pain and addiction faced by millions.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress